BackCRISPR Therapeutics AG Overview

CRISPR Therapeutics AG Current Cash

Track CRISPR Therapeutics AG's current cash ($420M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$423.31M
79.99% YoYΔ $188.12M vs prior year quarter

Peer average

Loading

CRISPR Therapeutics AG Current Cash History

Loading

CRISPR Therapeutics AG vs. peers: Current Cash Comparison

Loading

CRISPR Therapeutics AG Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

CRISPR Therapeutics AG (CRSP) FAQ

CRISPR Therapeutics AG (CRSP) currently reports a current cash of $420M as of March 2026. That compares with $240M in the prior-year period — up 80.0% year over year. Use the charts on this page to explore CRISPR Therapeutics AG's current cash history and peer comparisons.

CRISPR Therapeutics AG's current cash increased from $240M to $420M — a 80.0% year-over-year increase (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

CRISPR Therapeutics AG reported $420M in current cash as of March 2026. That compares with $240M in the prior-year period — up 80.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current current cash of $420M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for CRISPR Therapeutics AG, and consider following CRSP for alerts when major investors trade the stock.

CRISPR Therapeutics AG is classified in the Healthcare sector. On current cash, it currently shows $420M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CRSP with unrelated industries.